241 related articles for article (PubMed ID: 26190562)
21. The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools).
Wright DFB; Hishe HZ; Stocker SL; Dalbeth N; Horne A; Drake J; Haslett J; Phipps-Green AJ; Merriman TR; Stamp LK
Br J Clin Pharmacol; 2024 May; 90(5):1268-1279. PubMed ID: 38359899
[TBL] [Abstract][Full Text] [Related]
22. The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy.
Cao C; Gamble G; Horne A; Aati O; Doyle A; Drake J; Stamp LK; Dalbeth N
Rheumatology (Oxford); 2024 May; 63(6):1539-1542. PubMed ID: 37688559
[TBL] [Abstract][Full Text] [Related]
23. Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study.
Albert JA; Hosey T; LaMoreaux B
Rheumatol Ther; 2020 Sep; 7(3):639-648. PubMed ID: 32720081
[TBL] [Abstract][Full Text] [Related]
24. Adherence and Treat to Target Benchmarks in Older Adults with Gout Initiating Urate Lowering Therapy in Ontario, Canada: A Population-based Study.
Kwok TSH; Kuriya B; Hawker G; Eder L; Li P; Choy G; Widdifield J
Arthritis Care Res (Hoboken); 2024 Jun; ():. PubMed ID: 38831665
[TBL] [Abstract][Full Text] [Related]
25. Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice.
Singh JA; Richards JS; Chang E; Toupin-April K; Barton JL
Clin Rheumatol; 2021 Feb; 40(2):693-700. PubMed ID: 32997317
[TBL] [Abstract][Full Text] [Related]
26. Optimizing adherence to allopurinol for gout: patients' perspectives.
Spragg JCJ; Michael TJF; Aslani P; Coleshill MJ; Chan JS; Day RO; Stocker SL
Br J Clin Pharmacol; 2023 Jul; 89(7):1978-1991. PubMed ID: 36607199
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of tart cherry supplementary citrate mixture on gout patients: a prospective, randomized, controlled study.
Wang C; Sun W; Dalbeth N; Wang Z; Wang X; Ji X; Xue X; Han L; Cui L; Li X; Liu Z; Ji A; He Y; Sun M; Li C
Arthritis Res Ther; 2023 Sep; 25(1):164. PubMed ID: 37679816
[TBL] [Abstract][Full Text] [Related]
28. Study of febuxoat and allopurinol placebo in patients with high uric acid excretion and calcium stones.
Zhang H; Zhou L
Panminerva Med; 2024 Jun; 66(2):198-199. PubMed ID: 37535051
[No Abstract] [Full Text] [Related]
29. Changes in Prescription Drug and Health Care Use Over 9 Years After the Large Drug Price Increase for Colchicine.
Ly DP; Giuriato MA; Song Z
JAMA Intern Med; 2023 Jul; 183(7):670-676. PubMed ID: 37155179
[TBL] [Abstract][Full Text] [Related]
30. SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout.
Singh JA; Joseph A; Baker J; Richman JS; Shaneyfelt T; Saag KG; Eisen S
BMC Med; 2021 Nov; 19(1):265. PubMed ID: 34749717
[TBL] [Abstract][Full Text] [Related]
31. Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout.
Tedeschi SK; Hayashi K; Zhang Y; Choi H; Solomon DH
Ann Rheum Dis; 2024 May; ():. PubMed ID: 38724073
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial.
Liu S; Lin X; Tao M; Chen Q; Sun H; Han Y; Yang S; Gao Y; Qu S; Chen H
Lipids Health Dis; 2024 Mar; 23(1):77. PubMed ID: 38468241
[TBL] [Abstract][Full Text] [Related]
33. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.
Nielsen SM; Bartels EM; Henriksen M; Wæhrens EE; Gudbergsen H; Bliddal H; Astrup A; Knop FK; Carmona L; Taylor WJ; Singh JA; Perez-Ruiz F; Kristensen LE; Christensen R
Ann Rheum Dis; 2017 Nov; 76(11):1870-1882. PubMed ID: 28866649
[TBL] [Abstract][Full Text] [Related]
34. Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy.
Stamp LK; Horne A; Mihov B; Drake J; Haslett J; Chapman P; Frampton C; Dalbeth N
Arthritis Care Res (Hoboken); 2024 May; ():. PubMed ID: 38766703
[TBL] [Abstract][Full Text] [Related]
35. Treatment for acute flares of gout: A protocol for systematic review.
Tang H; Xu G; Zheng Q; Cheng Y; Zheng H; Li J; Yin Z; Liang F; Chen J
Medicine (Baltimore); 2020 Apr; 99(14):e19668. PubMed ID: 32243400
[TBL] [Abstract][Full Text] [Related]
36. Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110).
Kivitz A; DeHaan W; Azeem R; Park J; Rhodes S; Inshaw J; Leung SS; Nicolaou S; Johnston L; Kishimoto TK; Traber PG; Sands E; Choi H
Rheumatol Ther; 2023 Aug; 10(4):825-847. PubMed ID: 37069364
[TBL] [Abstract][Full Text] [Related]
37. Untangling the relationship between bempedoic acid and gout: results from a systematic literature review.
Alunno A; Carubbi F; Campanozzi E; Bellisario F; Schoones JW; Mariani FM; Di Ruscio E; Altieri P; Ferri C
Front Cardiovasc Med; 2023; 10():1234601. PubMed ID: 37953764
[TBL] [Abstract][Full Text] [Related]
38. Colorectal Cancer Among Gout Patients Undergoing Colonoscopy.
Slobodnick A; Krasnokutsky S; Lehmann RA; Keenan RT; Quach J; Francois F; Pillinger MH
J Clin Rheumatol; 2019 Dec; 25(8):335-340. PubMed ID: 31764494
[TBL] [Abstract][Full Text] [Related]
39. Effect of serum uric acid and gout on the incidence of colorectal cancer: A meta-analysis.
Liu Y; Chen W; Yang R; Zeng X; Zhang J
Am J Med Sci; 2024 Feb; 367(2):119-127. PubMed ID: 37984737
[TBL] [Abstract][Full Text] [Related]
40. Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Hammer HB
RMD Open; 2023 Dec; 9(4):. PubMed ID: 38053463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
